The U.S. Securities and Exchange Commission (SEC) has received an amended registration statement for the proposed 21Shares Injective ETF. This filing serves as a procedural update to a prior submission and is part of the SEC’s ongoing review process for the potential cryptocurrency-backed investment product. Crucially, this amended filing does not signify approval, and critical operational details, such as custody arrangements, remain unfinalized, according to the filing.
The amended S-1/A filing updates the original submission made in October 2025. Should it receive approval, the 21Shares Injective ETF aims to offer traditional investors regulated access to the INJ token, the native cryptocurrency of the Injective Network. The proposed ETF is slated to list on the Nasdaq under the ticker symbol TINJ and is structured as a Delaware statutory trust, sponsored by 21Shares US LLC.
ETF Strategy and Potential Yield
The ETF’s investment strategy is designed to passively track the performance of the INJ token via the FTSE Injective Index. A key component of this strategy involves the discretionary staking of a portion of the fund’s INJ holdings, a move intended to potentially enhance returns beyond simple price tracking. Historical data from 2025 indicates that annual staking rewards for INJ ranged between 9.3% and 13.62%, providing a yield component not typically found in traditional equity-focused exchange-traded funds.
Outstanding Uncertainties and Regulatory Hurdles
Despite this procedural step, significant regulatory hurdles remain. According to the filing, custody arrangements for the ETF’s assets are still unfinalized. This is a critical detail that the SEC will likely require to be resolved before considering any approval. The preliminary prospectus also states that shares have not yet traded publicly, and financial statements are not included at this stage.
Market Context and 21Shares’ Experience
The Injective Network is a layer-1 blockchain built on the Cosmos SDK, specifically engineered for decentralized finance (DeFi) applications, including decentralized exchanges and derivatives platforms. As of September 1, 2026, the circulating supply of INJ was approximately 92.8 million tokens, with a market capitalization near $488 million. This market capitalization is considerably smaller than major cryptocurrencies like Bitcoin or Ethereum, suggesting that even modest inflows into an INJ ETF could represent a significant percentage of the token’s total available supply.
21Shares has prior experience in bringing digital asset investment products to market. The firm currently offers a 21Shares Injective Staking ETP for European investors and was involved in the launch of the ARK 21Shares Bitcoin ETF in the U.S. The current filing for the Injective ETF aligns with a broader trend of asset managers seeking to launch ETFs for various layer-1 and DeFi tokens, following the introduction of spot Bitcoin and Ethereum ETFs in the U.S. in 2024.
The amended filing keeps the registration active and updated as the SEC continues its review. This process involves assessing the ETF’s structure, strategy, and operational readiness, including the finalization of custody arrangements. Whether the 21Shares Injective ETF will be approved by the SEC remains uncertain, as key details are still pending.
Why This Matters
The materials describe a narrow update: The SEC has received an amended registration statement (S-1/A) for the 21Shares Injective ETF, which aims to provide traditional investors with regulated access to the INJ token. Whether the 21Shares Injective ETF will be approved by the SEC.
